Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06604091
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-17
Brief Title:
Effect of Adenomyosis on ART Outcomes a Prospective Cohort Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effects of Adenomyosis on Pregnancy Outcomes in Women With Assisted Reproductive Technology a Prospective Cohort Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Previous studies have shown that compared with infertile women without adenomyosis the clinical pregnancy rate live birth rate and continuous pregnancy rate of women with adenomyosis significantly reduce and the abortion rate obviously increased However these studies lack a definite classification of adenomyosis so the true effect of adenomyosis with different severity on pregnancy outcomes are not clear Our research team intends to collect clinical data of infertility patients with adenomyosis receiving IVF and the detailed classification of adenomyosis according to MUSA criteria Finally we can have an objective recognition of adenomyosis on pregnancy outcomes which also bring benefits to evidence-based clinical practice
Detailed Description:
Previous studies have shown that compared with infertile women without adenomyosis the clinical pregnancy rate live birth rate and continuous pregnancy rate of women with adenomyosis significantly reduce and the abortion rate obviously increased However these studies lack a definite classification of adenomyosis so the true effect of adenomyosis with different severity on pregnancy outcomes are not clear Our research team intends to collect clinical data of infertility patients with adenomyosis receiving IVF and the detailed classification of adenomyosis according to MUSA and ultrasound consensus Finally we can have an objective recognition of adenomyosis on pregnancy outcomes which also bring benefits to evidence-based clinical practice
The detailed inclusion and exclusion criteria are as follows
Inclusion criteria
1Age of all participants 20 and 38 years 2Receiving IVF treatment because of adenomyosis or simple male factor 3Conforming to MUSA criteria 4 Body mass index 30 kgm2 5The level of AMH 08 ngml Exclusion criteria
1 Uterine fibroids International Federation of Gynecology and Obstetrics FIGO type 0--I--II or type III--IV fibroids 3 cm
2 Untreated endometrial polyps hydrosalpinx or uterine adhesions
3 RSA or RIF
4 Intracytoplasmic sperm injection ICSI and preimplantation genetic testing PGT
5 Concurrent andor recent involvement in other research within previous 3 months of study enrolment
The detailed inclusion and exclusion criteria are as follows
Inclusion criteria
1Age of all participants 20 and 38 years 2Receiving IVF treatment because of adenomyosis or simple male factor 3Conforming to MUSA criteria 4 Body mass index 30 kgm2 5The level of AMH 08 ngml Exclusion criteria
1 Uterine fibroids International Federation of Gynecology and Obstetrics FIGO type 0--I--II or type III--IV fibroids 3 cm
2 Untreated endometrial polyps hydrosalpinx or uterine adhesions
3 RSA or RIF
4 Intracytoplasmic sperm injection ICSI and preimplantation genetic testing PGT
5 Concurrent andor recent involvement in other research within previous 3 months of study enrolment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None